Our study is one of the largest-scale multicenter retrospective studies examining EGFR-TKI plus LCT for the treatment of advanced lung adenocarcinoma patients harboring susceptible EGFR mutations. This evidence concerns the gene EGFR and lung adenocarcinoma.